Literature DB >> 7925397

Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue.

S Zrihan-Licht1, H L Vos, A Baruch, O Elroy-Stein, D Sagiv, I Keydar, J Hilkens, D H Wreschner.   

Abstract

The human breast cancer marker protein, MUC1, is a polymorphic transmembrane molecule containing a large extracellular domain that is primarily composed of a variable number of highly conserved 20-amino-acid tandem repeats. We report here the detection of a novel invariantly sized 1.2-kb MUC1 mRNA, in addition to the large polymorphic mRNAs, by probing Northern blots with MUC1-cDNA-unique-sequence probes. The nucleotide sequence of this novel MUC1 mRNA demonstrates that it is identical to the MUC1 cDNA sequences downstream and upstream to the tandem-repeat array of the transmembrane form of MUC1. However, it contains neither the central tandem repeat array itself nor its directly flanking sequences that are deleted by a differential splicing event utilizing splice acceptor and donor sequences 5' and 3' to the tandem-repeat array. The splice event retains, downstream to the splice acceptor site, an open reading frame identical to that of the repeat-array-containing MUC1 thereby generating the novel MUC1/Y protein. Cells transiently transfected with the novel MUC1/Y cDNA express the MUC1/Y protein that is modified by glycosylation. The MUC1/Y protein is also readily detected in human breast cancer cells grown in vitro. Furthermore, primary breast cancer tissue samples demonstrate significant levels of the MUC1/Y protein whereas expression in tissue adjacent to the tumor is undetectable. Molecular characterization presented here, of the novel MUC1/Y molecule lacking the repeat array, suggests that it is likely to play a role distinct to that of the polymorphic repeat-array-positive MUC1 protein and that it may act as a new marker protein for human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7925397     DOI: 10.1111/j.1432-1033.1994.00787.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  19 in total

1.  Generation of ligand-receptor alliances by "SEA" module-mediated cleavage of membrane-associated mucin proteins.

Authors:  Daniel H Wreschner; Michael A McGuckin; Stefanie J Williams; Amos Baruch; Merav Yoeli; Ravit Ziv; Liron Okun; Joseph Zaretsky; Nechama Smorodinsky; Iafa Keydar; Pavlos Neophytou; Martin Stacey; His-Hsien Lin; Siamon Gordon
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

Review 2.  Mucins and blastocyst attachment.

Authors:  Amantha Thathiah; Daniel D Carson
Journal:  Rev Endocr Metab Disord       Date:  2002-05       Impact factor: 6.514

3.  O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.

Authors:  D Stepensky; E Tzehoval; E Vadai; L Eisenbach
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

4.  The SEA module: a new extracellular domain associated with O-glycosylation.

Authors:  P Bork; L Patthy
Journal:  Protein Sci       Date:  1995-07       Impact factor: 6.725

5.  Analysis of mammalian MUC1 genes reveals potential functionally important domains.

Authors:  A P Spicer; T Duhig; B S Chilton; S J Gendler
Journal:  Mamm Genome       Date:  1995-12       Impact factor: 2.957

6.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

Review 7.  Genetic variants of mucins: unexplored conundrum.

Authors:  Sushil Kumar; Eric Cruz; Suhasini Joshi; Asish Patel; Rahat Jahan; Surinder K Batra; Maneesh Jain
Journal:  Carcinogenesis       Date:  2017-07-01       Impact factor: 4.944

8.  Human mucin gene MUC5AC: organization of its 5'-region and central repetitive region.

Authors:  F Escande; J P Aubert; N Porchet; M P Buisine
Journal:  Biochem J       Date:  2001-09-15       Impact factor: 3.857

9.  Assay of mucins in human tear fluid.

Authors:  Sandra Spurr-Michaud; Pablo Argüeso; Ilene Gipson
Journal:  Exp Eye Res       Date:  2007-02-07       Impact factor: 3.467

10.  Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-β1/FAK/ERK pathway.

Authors:  Rahat Jahan; Muzafar A Macha; Satyanarayana Rachagani; Srustidhar Das; Lynette M Smith; Sukhwinder Kaur; Surinder K Batra
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-05-16       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.